Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial

被引：841

作者：

Thiele, Holger ^{[1
]}

Zeymer, Uwe ^{[2
,3
]}

Neumann, Franz-Josef ^{[4
]}

Ferenc, Miroslaw ^{[4
]}

Olbrich, Hans-Georg ^{[5
]}

Hausleiter, Joerg ^{[6
]}

de Waha, Antoinette ^{[7
]}

Richardt, Gert ^{[8
]}

Hennersdorf, Marcus ^{[9
]}

Empen, Klaus ^{[10
]}

Fuernau, Georg ^{[1
]}

Desch, Steffen ^{[1
]}

Eitel, Ingo ^{[1
]}

Hambrecht, Rainer ^{[11
]}

Lauer, Bernward ^{[12
]}

Boehm, Michael ^{[13
]}

Ebelt, Henning ^{[14
]}

Schneider, Steffen ^{[2
,3
]}

Werdan, Karl ^{[14
]}

Schuler, Gerhard ^{[1
]}

机构：

[1] Univ Leipzig, Ctr Heart, D-04289 Leipzig, Germany

[2] Klinikum Ludwigshafen, Ludwigshafen, Germany

[3] Inst Herzinfarktforsch, Ludwigshafen, Germany

[4] Univ Freiburg, Heart Ctr Bad Krozingen, Bad Krozingen, Germany

[5] Asklepios Clin Langen Seligenstadt, Langen, Germany

[6] Klinikum Ludwig Maximilians Univ Munchen, Munich, Germany

[7] German Heart Ctr Munich, Munich, Germany

[8] Segeberger Kliniken, Ctr Heart, Bad Segeberg, Germany

[9] SLK Kliniken Heilbronn, Heilbronn, Germany

[10] Ernst Moritz Arndt Univ Greifswald, Greifswald, Germany

[11] Klinikum Links Weser, Bremen, Germany

[12] Zent Klin Bad Berka, Bad Berka, Germany

[13] Univ Clin Saarland, Homburg, Germany

[14] Univ Halle Wittenberg, D-06108 Halle, Saale, Germany

来源：

LANCET | 2013年 / 382卷 / 9905期

关键词：

EARLY REVASCULARIZATION; PREDICTORS; MORTALITY; SURVIVAL; GUIDELINES; MANAGEMENT; TRENDS; ESC;

D O I：

10.1016/S0140-6736(13)61783-3

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Background In current international guidelines the recommendation for intra-aortic balloon pump (IABP) use has been downgraded in cardiogenic shock complicating acute myocardial infarction on the basis of registry data. In the largest randomised trial (IABP-SHOCK II), IABP support did not reduce 30 day mortality compared with control. However, previous trials in cardiogenic shock showed a mortality benefit only at extended follow-up. The present analysis therefore reports 6 and 12 month results. Methods The IABP-SHOCK II trial was a randomised, open-label, multicentre trial. Patients with cardiogenic shock complicating acute myocardial infarction who were undergoing early revascularisation and optimum medical therapy were randomly assigned (1:1) to IABP versus control via a central web-based system. The primary efficacy endpoint was 30 day all-cause mortality, but 6 and 12 month follow-up was done in addition to quality-of-life assessment for all survivors with the Euroqol-5D questionnaire. A masked central committee adjudicated clinical outcomes. Patients and investigators were not masked to treatment allocation. Analysis was by intention to treat. This trial is registered at ClinicalTrials.gov, NCT00491036. Findings Between June 16, 2009, and March 3, 2012, 600 patients were assigned to IABP (n=301) or control (n=299). Of 595 patients completing 12 month follow-up, 155 (52%) of 299 patients in the IABP group and 152 (51%) of 296 patients in the control group had died (relative risk [RR] 1.01, 95% CI 0.86-1.18, p=0.91). There were no significant differences in reinfarction (RR 2.60, 95% CI 0.95-7.10, p=0.05), recurrent revascularisation (0.91, 0.58-1.41, p=0.77), or stroke (1.50, 0.25-8.84, p=1.00). For survivors, quality-of-life measures including mobility, self-care, usual activities, pain or discomfort, and anxiety or depression did not differ significantly between study groups. Interpretation In patients undergoing early revascularisation for myocardial infarction complicated by cardiogenic shock, IABP did not reduce 12 month all-cause mortality.

引用

页码：1638 / 1645

页数：8

共 30 条

[1]

Comparison of Hospital Mortality With Intra-Aortic Balloon Counterpulsation Insertion Before Versus After Primary Percutaneous Coronary Intervention for Cardiogenic Shock Complicating Acute Myocardial Infarction [J].